Company intelligence / Profile preview

Daya Drug Discoveries

Monmouth Junction, New Jersey, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Daya Drug Discoveries is a preclinical-stage biotechnology company specializing in the discovery of small molecule drugs that modulate protein-protein interactions (PPIs). The company employs a proprietary structure-based design platform to target proteins previously considered undruggable, with a particular focus on oncogenic drivers and inflammatory mediators. Their lead programs include inhibitors targeting KRAS and MYC for various cancer indications. Headquartered in New Jersey, the firm integrates computational biology and medicinal chemistry to develop high-affinity, selective therapeutic candidates.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Daya Drug Discoveries.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Daya Drug Discoveries.

Explore the full profile